R&D News | pharmaphorum

News

Vabysmo vaults into Roche’s top growth spot

The undisputed star of Roche’s pharma portfolio in the first quarter of this year is eye disease therapy Vabysmo, heading for blockbuster territory after posting sales of

News

Last year’s UK biotech financing dip extends into 2023

The first quarter of 2023 saw just £295 million raised by UK-based life sciences and biotech companies, signalling that investor confidence remains low after a disappointi

News

Vedanta scores $106.5m to take microbiome drug into ph3

In the face of a challenging biotech financing environment, Vedanta Bio has ra

News

Lilly goes toe-to-toe with Novo Nordisk on obesity

Eli Lilly has raised the stakes in its looming battle with Novo Nordisk in the market for obesity drugs, planning a clinical trial that will directly compare its new thera

News

Novartis cuts 10% of R&D projects in ‘focused’ strategy

Novartis revealed this morning that it has decided to trim back its R&D pipeline by around 10% to 136 projects, as it continues its transition into a pure-play innovat

News

AZ, Ionis hail phase 3 data for ATTR drug eplontersen

AstraZeneca have broken out the data they teased last month for transthyretin amyloidosis (ATTR) therapy eplontersen, showing that the drug was effective at slowing down d

Vabysmo vaults into Roche’s top growth spot

Last year’s UK biotech financing dip extends into 2023

Vedanta scores $106.5m to take microbiome drug into ph3

Lilly goes toe-to-toe with Novo Nordisk on obesity

Novartis cuts 10% of R&D projects in ‘focused’ strategy

AZ, Ionis hail phase 3 data for ATTR drug eplontersen

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks